{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:02:37Z","timestamp":1788850957788,"version":"build-2803163510"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23-DK109203"],"award-info":[{"award-number":["K23-DK109203"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["T32-DK007785"],"award-info":[{"award-number":["T32-DK007785"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00467-020-04869-w","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T01:02:36Z","timestamp":1611190956000},"page":"2639-2658","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Predictors of progression in autosomal dominant and autosomal recessive polycystic kidney disease"],"prefix":"10.1007","volume":"36","author":[{"given":"Eric G.","family":"Benz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5617-6505","authenticated-orcid":false,"given":"Erum A.","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,21]]},"reference":[{"key":"4869_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","volume":"4","author":"C Bergmann","year":"2018","unstructured":"Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE (2018) Polycystic kidney disease. Nat Rev Dis Prim 4:50. https:\/\/doi.org\/10.1038\/s41572-018-0047-y","journal-title":"Nat Rev Dis Prim"},{"key":"4869_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s004670050281","volume":"11","author":"S Roy","year":"1997","unstructured":"Roy S, Dillon MJ, Trompeter RS, Barratt TM (1997) Autosomal recessive polycystic kidney disease: long-term outcome of neonatal survivors. Pediatr Nephrol 11:302\u2013306. https:\/\/doi.org\/10.1007\/s004670050281","journal-title":"Pediatr Nephrol"},{"key":"4869_CR3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/j.1523-1755.2005.00148.x","volume":"67","author":"C Bergmann","year":"2005","unstructured":"Bergmann C, Senderek J, Windelen E, K\u00fcpper F, Middeldorf I, Schneider F, Dornia C, Rudnik-Sch\u00f6neborn S, Konrad M, Schmitt CP, Seeman T, Neuhaus TJ, Vester U, Kirfel J, B\u00fcttner R, Zerres K, Abel E, Ala-Mello S, Ausserer B, Bald M, Beetz R, Besbas N, Brandis M, Coulthard M, Dippel J, Garcia CD, Fischbach M, Foged N, Frishberg Y, Gellermann J, Gordjani N, H\u00e4ffner K, Hennekam RC, Hoppe B, Hoyer P, John U, K\u00e4\u00e4ri\u00e4inen H, Kemper MJ, Koivisto P, Kr\u00fcger G, Kuwertz-Br\u00f6cking E, Lambert D, Lennert T, Li Volti S, Mache C, Matthijs G, Mehls O, Meiner V, Misselwitz J, Mononen T, M\u00fcller-Wiefel DE, Mustonen A, \u00d6zen S, Oliveira JP, Pirson Y, Querfeld U, Rascher W, Rudin C, Santos HG, Schr\u00f6der M, Seyberth HW, Shalev S, Shohat M, Strehlau J, Vierimaa O, V\u00f6lpel S, Wilson M, Zimmerhackl B (2005) Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD). Kidney Int 67:829\u2013848. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00148.x","journal-title":"Kidney Int"},{"key":"4869_CR4","doi-asserted-by":"publisher","first-page":"7919","DOI":"10.1038\/s41598-019-43488-w","volume":"9","author":"K Burgmaier","year":"2019","unstructured":"Burgmaier K, Kilian S, Bammens B, Benzing T, Billing H, B\u00fcscher A, Galiano M, Grundmann F, Klaus G, Mekahli D, Michel-Calemard L, Milosevski-Lomic G, Ranchin B, Sauerstein K, Schaefer S, Shroff R, Sterenborg R, Verbeeck S, Weber LT, Wicher D, W\u00fchl E, D\u00f6tsch J, Schaefer F, Liebau MC (2019) Clinical courses and complications of young adults with Autosomal Recessive Polycystic Kidney Disease (ARPKD). Sci Rep 9:7919. https:\/\/doi.org\/10.1038\/s41598-019-43488-w","journal-title":"Sci Rep"},{"key":"4869_CR5","doi-asserted-by":"publisher","first-page":"972","DOI":"10.2215\/CJN.07141009","volume":"5","author":"M Gunay-Aygun","year":"2010","unstructured":"Gunay-Aygun M, Font-Montgomery E, Lukose L, Tuchman M, Graf J, Bryant JC, Kleta R, Garcia A, Edwards H, Piwnica-Worms K, Adams D, Bernardini I, Fischer RE, Krasnewich D, Oden N, Ling A, Quezado Z, Zak C, Daryanani KT, Turkbey B, Choyke P, Guay-Woodford LM, Gahl WA (2010) Correlation of kidney function, volume and imaging findings, and PKHD1 mutations in 73 patients with autosomal recessive polycystic kidney disease. Clin J Am Soc Nephrol 5:972\u2013984. https:\/\/doi.org\/10.2215\/CJN.07141009","journal-title":"Clin J Am Soc Nephrol"},{"key":"4869_CR6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3389\/fped.2017.00272","volume":"5","author":"S De Rechter","year":"2017","unstructured":"De Rechter S, Breysem L, Mekahli D (2017) Is autosomal dominant polycystic kidney disease becoming a pediatric disorder? Front Pediatr 5:272. https:\/\/doi.org\/10.3389\/fped.2017.00272","journal-title":"Front Pediatr"},{"key":"4869_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cgh.2014.07.051","volume":"13","author":"MC Hogan","year":"2014","unstructured":"Hogan MC, Abebe K, Torres VE, Chapman AB, Bae KT, Tao C, Sun H, Perrone RD, Steinman TI, Braun W, Winklhofer FT, Miskulin DC, Rahbari-Oskoui F, Brosnahan G, Masoumi A, Karpov IO, Spillane S, Flessner M, Moore CG, Schrier RW (2014) Liver involvement in early autosomal dominant polycystic kidney disease. Clin Gastroenterol Hepatol 13:155\u2013164. https:\/\/doi.org\/10.1016\/j.cgh.2014.07.051","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4869_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-013-2706-2","volume":"30","author":"C Bergmann","year":"2015","unstructured":"Bergmann C (2015) ARPKD and early manifestations of ADPKD: the original polycystic kidney disease and phenocopies. Pediatr Nephrol 30:15\u201330","journal-title":"Pediatr Nephrol"},{"key":"4869_CR9","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ajhg.2018.03.013","volume":"102","author":"E Cornec-Le Gall","year":"2018","unstructured":"Cornec-Le Gall E, Olson RJ, Besse W, Heyer CM, Gainullin VG, Smith JM, Audr\u00e9zet M-P, Hopp K, Porath B, Shi B, Baheti S, Senum SR, Arroyo J, Madsen CD, F\u00e9rec C, Joly D, Jouret F, Fikri-Benbrahim O, Charasse C, Coulibaly J-M, Yu AS, Khalili K, Pei Y, Somlo S, Le Meur Y, Torres VE, Genkyst Study Group, HALT Progression of Polycystic Kidney Disease Group, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease, Harris PC (2018) Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease. Am J Hum Genet 102:832\u2013844. https:\/\/doi.org\/10.1016\/j.ajhg.2018.03.013","journal-title":"Am J Hum Genet"},{"key":"4869_CR10","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","volume":"98","author":"B Porath","year":"2016","unstructured":"Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, Edwards ME, Madsen CD, Mauritz SR, Banks CJ, Baheti S, Reddy B, Herrero JI, Ba\u00f1ales JM, Hogan MC, Tasic V, Watnick TJ, Chapman AB, Vigneau C, Lavainne F, Audr\u00e9zet MP, Ferec C, Le Meur Y, Torres VE, Harris PC (2016) mutations in GANAB, encoding the glucosidase II\u03b1 subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet 98:1193\u20131207. https:\/\/doi.org\/10.1016\/j.ajhg.2016.05.004","journal-title":"Am J Hum Genet"},{"key":"4869_CR11","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","volume":"393","author":"E Cornec-Le Gall","year":"2019","unstructured":"Cornec-Le Gall E, Alam A, Perrone RD (2019) Autosomal dominant polycystic kidney disease. Lancet 393:919\u2013935. https:\/\/doi.org\/10.1016\/S0140-6736(18)32782-X","journal-title":"Lancet"},{"key":"4869_CR12","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.1172\/JCI67273","volume":"124","author":"Y Cai","year":"2014","unstructured":"Cai Y, Fedeles SV, Dong K, Anyatonwu G, Onoe T, Mitobe M, Gao JD, Okuhara D, Tian X, Gallagher AR, Tang Z, Xie X, Lalioti MD, Lee AH, Ehrlich BE, Somlo S (2014) Altered trafficking and stability of polycystins underlie polycystic kidney disease. J Clin Invest 124:5129\u20135144. https:\/\/doi.org\/10.1172\/JCI67273","journal-title":"J Clin Invest"},{"key":"4869_CR13","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1681\/ASN.2012070650","volume":"24","author":"E Cornec-Le Gall","year":"2013","unstructured":"Cornec-Le Gall E, Audr\u00e9zet M-P, Chen J-M, Hourmant M, Morin M-P, Perrichot R, Charasse C, Whebe B, Renaudineau E, Jousset P, Guillodo M-P, Grall-Jezequel A, Saliou P, F\u00e9rec C, Le Meur Y (2013) Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 24:1006\u20131013. https:\/\/doi.org\/10.1681\/ASN.2012070650","journal-title":"J Am Soc Nephrol"},{"key":"4869_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/jcm9010146","volume":"9","author":"H Kataoka","year":"2020","unstructured":"Kataoka H, Fukuoka H, Makabe S, Yoshida R, Teraoka A, Ushio Y, Akihisa T, Manabe S, Sato M, Mitobe M, Tsuchiya K, Nitta K, Mochizuki T (2020) Prediction of renal prognosis in patients with autosomal dominant polycystic kidney disease using PKD1\/PKD2 mutations. J Clin Med 9:146. https:\/\/doi.org\/10.3390\/jcm9010146","journal-title":"J Clin Med"},{"key":"4869_CR15","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1681\/ASN.2010101080","volume":"22","author":"C Bergmann","year":"2011","unstructured":"Bergmann C, Von Bothmer J, Bru NO, Frank V, Fehrenbach H, Hampel T, Pape L, Buske A, Jonsson J, Sarioglu N, Ferreira JC, Becker JU, Cremer R, Hoefele J, Benz MR, Weber LT, Buettner R, Zerres K, von Bothmer J, Ortiz Bruchle N, Venghaus A, Santos A (2011) Mutations in multiple PKD genes may explain early and severe polycystic kidney disease. J Am Soc Nephrol 22:2047\u20132056. https:\/\/doi.org\/10.1681\/ASN.2010101080","journal-title":"J Am Soc Nephrol"},{"key":"4869_CR16","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/ki.2008.686","volume":"75","author":"S Rossetti","year":"2009","unstructured":"Rossetti S, Kubly VJ, Consugar MB, Hopp K, Roy S, Horsley SW, Chauveau D, Rees L, Barratt TM, Van\u2019t Hoff WG, Niaudet WP, Torres VE, Harris PC (2009) Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int 75:848\u2013855. https:\/\/doi.org\/10.1038\/ki.2008.686","journal-title":"Kidney Int"},{"key":"4869_CR17","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1681\/ASN.2014101051","volume":"27","author":"MP Audr\u00e9zet","year":"2016","unstructured":"Audr\u00e9zet MP, Corbiere C, Lebbah S, Morini\u00e8re V, Broux F, Louillet F, Fischbach M, Zaloszyc A, Cloarec S, Merieau E, Baudouin V, Desch\u00eanes G, Roussey G, Maestri S, Visconti C, Boyer O, Abel C, Lahoche A, Randrianaivo H, Bessenay L, Mekahli D, Ouertani I, Decramer S, Ryckenwaert A, Le Gall EC, Salomon R, Ferec C, Heidet L (2016) Comprehensive PKD1 and PKD2 mutation analysis in prenatal autosomal dominant polycystic kidney disease. J Am Soc Nephrol 27:722\u2013729. https:\/\/doi.org\/10.1681\/ASN.2014101051","journal-title":"J Am Soc Nephrol"},{"key":"4869_CR18","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1681\/ASN.2009101070","volume":"21","author":"M Vujic","year":"2010","unstructured":"Vujic M, Heyer CM, Ars E, Hopp K, Markoff A, \u00d6rndal C, Rudenhed B, Nasr SH, Torres VE, Torra R, Bogdanova N, Harris PC (2010) Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD. J Am Soc Nephrol 21:1097\u20131102. https:\/\/doi.org\/10.1681\/ASN.2009101070","journal-title":"J Am Soc Nephrol"},{"key":"4869_CR19","first-page":"164","volume":"6","author":"S Pandita","year":"2017","unstructured":"Pandita S, Maurya D, Ramachandran V, Verma J, Kohli S, Saxena R, Verma IC (2017) Vascular endothelial growth factor (VEGF) gene promoter polymorphisms and disease progression in North Indian cohort with autosomal dominant polycystic kidney disease. Int J Mol Cell Med 6:164\u2013173","journal-title":"Int J Mol Cell Med"},{"key":"4869_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/ki.2010.355","volume":"79","author":"B Reed","year":"2011","unstructured":"Reed B, Ph D, Masoumi A, Elhassan E, Mcfann K, Ph D, Cadnapaphornchai M, Maahs D, Snell-bergeon J, Ph D, Schrier RW (2011) Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease. Kidney Int 79:128\u2013134. https:\/\/doi.org\/10.1038\/ki.2010.355","journal-title":"Kidney Int"},{"key":"4869_CR21","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1111\/j.1523-1755.2004.66003.x","volume":"66","author":"A Persu","year":"2004","unstructured":"Persu A, Duyme M, Pirson Y, Lens XM, Messiaen T, Breuning MH, Chauveau D, Levy M, Gr\u00fcnfeld JP, Devuyst O (2004) Comparison between siblings and twins supports a role for modifier genes in ADPKD. Kidney Int 66:2132\u20132136. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.66003.x","journal-title":"Kidney Int"},{"key":"4869_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000448695","volume":"44","author":"KL Nowak","year":"2016","unstructured":"Nowak KL, Cadnapaphornchai MA, Chonchol MB, Schrier RW, Gitomer B (2016) Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol 44:171\u2013178. https:\/\/doi.org\/10.1159\/000448695","journal-title":"Am J Nephrol"},{"key":"4869_CR23","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1111\/j.1523-1755.2005.00678.x","volume":"68","author":"A Shamshirsaz","year":"2005","unstructured":"Shamshirsaz A, Bekheirnia RM, Kamgar M, Johnson AM, McFann K, Cadnapaphornchai M, Haghighi NN, Schrier RW (2005) Autosomal-dominant polycystic kidney disease in infancy and childhood: progression and outcome. Kidney Int 68:2218\u20132224. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00678.x","journal-title":"Kidney Int"},{"key":"4869_CR24","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s00467-010-1617-8","volume":"25","author":"D Mekahli","year":"2010","unstructured":"Mekahli D, Woolf AS, Bockenhauer D (2010) Similar renal outcomes in children with ADPKD diagnosed by screening or presenting with symptoms. Pediatr Nephrol 25:2275\u20132282. https:\/\/doi.org\/10.1007\/s00467-010-1617-8","journal-title":"Pediatr Nephrol"},{"key":"4869_CR25","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1053\/j.ajkd.2003.12.026","volume":"43","author":"H Wong","year":"2004","unstructured":"Wong H, Vivian L, Weiler G, Filler G (2004) Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease. Am J Kidney Dis 43:624\u2013628","journal-title":"Am J Kidney Dis"},{"key":"4869_CR26","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.2215\/CJN.01010211","volume":"6","author":"I Helal","year":"2011","unstructured":"Helal I, Reed B, McFann K, Yan X-D, Fick-Brosnahan GM, Cadnapaphornchai M, Schrier RW (2011) Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6:2439\u20132443. https:\/\/doi.org\/10.2215\/CJN.01010211","journal-title":"Clin J Am Soc Nephrol"},{"key":"4869_CR27","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1681\/ASN.2008080882","volume":"20","author":"RW Schrier","year":"2009","unstructured":"Schrier RW (2009) Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 20:1888\u20131893","journal-title":"J Am Soc Nephrol"},{"key":"4869_CR28","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s00467-012-2192-y","volume":"27","author":"L Selistre","year":"2012","unstructured":"Selistre L, De Souza V, Ranchin B, Hadj-Aissa A, Cochat P, Dubourg L (2012) Early renal abnormalities in children with postnatally diagnosed autosomal dominant polycystic kidney disease. Pediatr Nephrol 27:1589\u20131593. https:\/\/doi.org\/10.1007\/s00467-012-2192-y","journal-title":"Pediatr Nephrol"},{"key":"4869_CR29","first-page":"629","volume":"53","author":"T Seeman","year":"2004","unstructured":"Seeman T, Du\u0161ek J, Vondr\u00e1k K, Bl\u00e1hov\u00e1 K, \u0160imkov\u00e1 E, Kreisinger J, Dvo\u0159\u00e1k P, Kyn\u010dl M, H\u0159\u00edbal Z, Janda J (2004) Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease. Physiol Res 53:629\u2013634","journal-title":"Physiol Res"},{"key":"4869_CR30","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/ki.1992.195","volume":"41","author":"PA Gabow","year":"1992","unstructured":"Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, Jones RH (1992) Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 41:1311\u20131319. https:\/\/doi.org\/10.1038\/ki.1992.195","journal-title":"Kidney Int"},{"key":"4869_CR31","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1681\/ASN.2015010016","volume":"27","author":"E Cornec-Le Gall","year":"2016","unstructured":"Cornec-Le Gall E, Audr\u00e9zet M-P, Rousseau A, Hourmant M, Renaudineau E, Charasse C, Morin M-P, Moal M-C, Dantal J, Wehbe B, Perrichot R, Frouget T, Vigneau C, Potier J, Jousset P, Guillodo M-P, Siohan P, Terki N, Sawadogo T, Legrand D, Menoyo-Calonge V, Benarbia S, Besnier D, Longuet H, F\u00e9rec C, Le Meur Y (2016) The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 27:942\u2013951. https:\/\/doi.org\/10.1681\/ASN.2015010016","journal-title":"J Am Soc Nephrol"},{"key":"4869_CR32","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1681\/ASN.V9101908","volume":"9","author":"C Sharp","year":"1998","unstructured":"Sharp C, Johnson A, Gabow P (1998) Factors relating to urinary protein excretion in children with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 9:1908\u20131914","journal-title":"J Am Soc Nephrol"},{"key":"4869_CR33","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1681\/ASN.V561349","volume":"5","author":"AB Chapman","year":"1994","unstructured":"Chapman AB, Johnson AM, Gabow PA, Schrier RW (1994) Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5:1349\u20131354","journal-title":"J Am Soc Nephrol"},{"key":"4869_CR34","doi-asserted-by":"publisher","first-page":"820","DOI":"10.2215\/CJN.02810608","volume":"4","author":"MA Cadnapaphornchai","year":"2009","unstructured":"Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW (2009) Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol 4:820\u2013829. https:\/\/doi.org\/10.2215\/CJN.02810608","journal-title":"Clin J Am Soc Nephrol"},{"key":"4869_CR35","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41581-019-0155-2","volume":"15","author":"C Gimpel","year":"2019","unstructured":"Gimpel C, Bergmann C, Bockenhauer D, Breysem L, Cadnapaphornchai MA, Cetiner M, Dudley J, Emma F, Konrad M, Harris T, Harris PC, K\u00f6nig J, Liebau MC, Marlais M, Mekahli D, Metcalfe AM, Oh J, Perrone RD, Sinha MD, Titieni A, Torra R, Weber S, Winyard PJD, Schaefer F (2019) International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people. Nat Rev Nephrol 15:713\u2013726. https:\/\/doi.org\/10.1038\/s41581-019-0155-2","journal-title":"Nat Rev Nephrol"},{"key":"4869_CR36","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12882-019-1285-2","volume":"20","author":"J Dudley","year":"2019","unstructured":"Dudley J, Winyard P, Marlais M, Cuthell O, Harris T, Chong J, Sayer J, Gale DP, Moore L, Turner K, Burrows S, Sandford R (2019) Clinical practice guideline monitoring children and young people with, or at risk of developing autosomal dominant polycystic kidney disease (ADPKD). BMC Nephrol 20:148. https:\/\/doi.org\/10.1186\/s12882-019-1285-2","journal-title":"BMC Nephrol"},{"key":"4869_CR37","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","volume":"371","author":"RW Schrier","year":"2014","unstructured":"Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB (2014) Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 371:2255\u20132266. https:\/\/doi.org\/10.1056\/NEJMoa1402685","journal-title":"N Engl J Med"},{"key":"4869_CR38","doi-asserted-by":"publisher","first-page":"CJN.11401017","DOI":"10.2215\/CJN.11401017","volume":"13","author":"L Massella","year":"2018","unstructured":"Massella L, Mekahli D, Paripovi\u0107 D, Prikhodina L, Godefroid N, Niemirska A, A\u011fba\u015f A, Kalicka K, Jankauskiene A, Mizerska-Wasiak M, Afonso AC, Salomon R, Desch\u00eanes G, Ariceta G, \u00d6z\u00e7akar ZB, Teixeira A, Duzova A, Harambat J, Seeman T, Hr\u010dkov\u00e1 G, Lungu AC, Papizh S, Peco-Antic A, De Rechter S, Giordano U, Kirchner M, Lutz T, Schaefer F, Devuyst O, W\u00fchl E, Emma F (2018) Prevalence of hypertension in children with early-stage ADPKD. Clin J Am Soc Nephrol 13:CJN.11401017. https:\/\/doi.org\/10.2215\/CJN.11401017","journal-title":"Clin J Am Soc Nephrol"},{"key":"4869_CR39","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1038\/ki.1990.330","volume":"38","author":"PA Gabow","year":"1990","unstructured":"Gabow PA, Chapman AB, Johnson AM, Tangel TJ, Duley IT, Kaehny WD, Manco-Johnson M, Schrier RW (1990) Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 38:1177\u20131180. https:\/\/doi.org\/10.1038\/ki.1990.330","journal-title":"Kidney Int"},{"key":"4869_CR40","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1093\/ndt\/gfg417","volume":"18","author":"MA van Dijk","year":"2003","unstructured":"van Dijk MA, Breuning MH, Duiser R, van Es LA, Westendorp RGJ (2003) No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 18:2314\u20132320. https:\/\/doi.org\/10.1093\/ndt\/gfg417","journal-title":"Nephrol Dial Transplant"},{"key":"4869_CR41","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000046231","volume":"21","author":"T Ecder","year":"2001","unstructured":"Ecder T, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Chapman AB, Gabow PA, Schrier RW (2001) Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol 21:98\u2013103. https:\/\/doi.org\/10.1159\/000046231","journal-title":"Am J Nephrol"},{"key":"4869_CR42","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1523-1755.2005.00077.x","volume":"67","author":"TH Jafar","year":"2005","unstructured":"Jafar TH, Stark PC, Schmid CH, Strandgaard S, Kamper AL, Maschio G, Becicer G, Perrone RD, Levey AS (2005) The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int 67:265\u2013271. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00077.x","journal-title":"Kidney Int"},{"key":"4869_CR43","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000081790","volume":"99","author":"K Nutahara","year":"2005","unstructured":"Nutahara K, Higashihara E, Horie S, Kamura K, Tsuchiya K, Mochizuki T, Hosoya T, Nakayama T, Yamamoto N, Higaki Y, Shimizu T (2005) Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract 99:18\u201323. https:\/\/doi.org\/10.1159\/000081790","journal-title":"Nephron Clin Pract"},{"key":"4869_CR44","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s00467-018-4004-5","volume":"34","author":"A Andries","year":"2019","unstructured":"Andries A, Daenen K, Jouret F, Bammens B, Mekahli D, Van Schepdael A (2019) Oxidative stress in autosomal dominant polycystic kidney disease: player and\/or early predictor for disease progression? Pediatr Nephrol 34:993\u20131008","journal-title":"Pediatr Nephrol"},{"key":"4869_CR45","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.2215\/CJN.05850518","volume":"13","author":"KL Nowak","year":"2018","unstructured":"Nowak KL, Wang W, Farmer-Bailey H, Gitomer B, Malaczewski M, Klawitter J, Jovanovich A, Chonchol M (2018) Vascular dysfunction, oxidative stress, and inflammation in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 13:1493\u20131501. https:\/\/doi.org\/10.2215\/CJN.05850518","journal-title":"Clin J Am Soc Nephrol"},{"key":"4869_CR46","doi-asserted-by":"publisher","first-page":"640","DOI":"10.2215\/CJN.03250410","volume":"6","author":"VE Torres","year":"2011","unstructured":"Torres VE, Grantham JJ, Chapman AB, Mrug M, Bae KT, King BF, Wetzel LH, Martin D, Lockhart ME, Bennett WM, Moxey-Mims M, Abebe KZ, Lin Y, Bost JE (2011) Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6:640\u2013647. https:\/\/doi.org\/10.2215\/CJN.03250410","journal-title":"Clin J Am Soc Nephrol"},{"key":"4869_CR47","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1681\/ASN.2006080835","volume":"17","author":"PC Harris","year":"2006","unstructured":"Harris PC, Bae KT, Rossetti S, Torres VE, Grantham JJ, Chapman AB, Guay-Woodford LM, King BF, Wetzel LH, Baumgarten DA, Kenney PJ, Consugar M, Klahr S, Bennett WM, Meyers CM, Zhang Q, Thompson PA, Zhu F, Miller JP (2006) Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 17:3013\u20133019. https:\/\/doi.org\/10.1681\/ASN.2006080835","journal-title":"J Am Soc Nephrol"},{"key":"4869_CR48","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2215\/CJN.09500911","volume":"7","author":"AB Chapman","year":"2012","unstructured":"Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, Li J, King BF, Martin D, Wetzel LH, Lockhart ME, Harris PC, Moxey-Mims M, Flessner M, Bennett WM, Grantham JJ (2012) Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 7:479\u2013486. https:\/\/doi.org\/10.2215\/CJN.09500911","journal-title":"Clin J Am Soc Nephrol"},{"key":"4869_CR49","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2215\/CJN.03780410","volume":"6","author":"MA Cadnapaphornchai","year":"2011","unstructured":"Cadnapaphornchai MA, Masoumi A, Strain JD, McFann K, Schrier RW (2011) Magnetic resonance imaging of kidney and cyst volume in children with ADPKD. Clin J Am Soc Nephrol 6:369\u2013376. https:\/\/doi.org\/10.2215\/CJN.03780410","journal-title":"Clin J Am Soc Nephrol"},{"key":"4869_CR50","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.kint.2017.09.027","volume":"93","author":"ASL Yu","year":"2018","unstructured":"Yu ASL, Shen C, Landsittel DP, Harris PC, Torres VE, Mrug M, Bae KT, Grantham JJ, Rahbari-Oskoui FF, Flessner MF, Bennett WM, Chapman AB, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) (2018) Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int 93:691\u2013699. https:\/\/doi.org\/10.1016\/j.kint.2017.09.027","journal-title":"Kidney Int"},{"key":"4869_CR51","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1053\/j.ajkd.2005.08.026","volume":"46","author":"WC O\u2019Neill","year":"2005","unstructured":"O\u2019Neill WC, Robbin ML, Bae KT, Grantham JJ, Chapman AB, Guay-Woodford LM, Torres VE, King BF, Wetzel LH, Thompson PA, Miller JP (2005) Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP). Am J Kidney Dis 46:1058\u20131064. https:\/\/doi.org\/10.1053\/j.ajkd.2005.08.026","journal-title":"Am J Kidney Dis"},{"key":"4869_CR52","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","volume":"64","author":"AB Chapman","year":"2003","unstructured":"Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, Kenney PJ, King BF, Glockner JF, Wetzel LH, Brummer ME, O\u2019Neill WC, Robbin ML, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP (2003) Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 64:1035\u20131045. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00185.x","journal-title":"Kidney Int"},{"key":"4869_CR53","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00467-017-3862-6","volume":"33","author":"L Breysem","year":"2018","unstructured":"Breysem L, De Rechter S, De Keyzer F, Smet MH, Bammens B, Van Dyck M, Hofmans M, Oyen R, Levtchenko E, Mekahli D (2018) 3DUS as an alternative to MRI for measuring renal volume in children with autosomal dominant polycystic kidney disease. Pediatr Nephrol 33:827\u2013835. https:\/\/doi.org\/10.1007\/s00467-017-3862-6","journal-title":"Pediatr Nephrol"},{"key":"4869_CR54","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/ki.2015.71","volume":"88","author":"H Bhutani","year":"2015","unstructured":"Bhutani H, Smith V, Rahbari-Oskoui F, Mittal A, Grantham JJ, Torres VE, Mrug M, Bae KT, Wu Z, Ge Y, Landslittel D, Gibbs P, O\u2019Neill WC, Chapman AB, CRISP Investigators (2015) A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int 88:146\u2013151. https:\/\/doi.org\/10.1038\/ki.2015.71","journal-title":"Kidney Int"},{"key":"4869_CR55","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ekir.2017.01.003","volume":"2","author":"RD Perrone","year":"2017","unstructured":"Perrone RD, Mouksassi MS, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, Torres VE, Miskulin DC, Broadbent S, Marier JF (2017) Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease. Kidney Int Rep 2:442\u2013450. https:\/\/doi.org\/10.1016\/j.ekir.2017.01.003","journal-title":"Kidney Int Rep"},{"key":"4869_CR56","unstructured":"US Food and Drug Administration. Biomarker Qualification Program. https:\/\/www.fda.gov\/drugs\/cder-biomarker-qualification-program\/list-qualified-biomarkers. Accessed 27 Apr 2020"},{"key":"4869_CR57","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407\u20132418. https:\/\/doi.org\/10.1056\/NEJMoa1205511","journal-title":"N Engl J Med"},{"key":"4869_CR58","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00467-015-3104-8","volume":"31","author":"EA Hartung","year":"2016","unstructured":"Hartung EA (2016) Biomarkers and surrogate endpoints in kidney disease. Pediatr Nephrol 31:381\u2013391. https:\/\/doi.org\/10.1007\/s00467-015-3104-8","journal-title":"Pediatr Nephrol"},{"key":"4869_CR59","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.kint.2017.03.026","volume":"92","author":"TL Kline","year":"2017","unstructured":"Kline TL, Korfiatis P, Edwards ME, Bae KT, Yu A, Chapman AB, Mrug M, Grantham JJ, Landsittel D, Bennett WM, King BF, Harris PC, Torres VE, Erickson BJ (2017) Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease. Kidney Int 92:1206\u20131216. https:\/\/doi.org\/10.1016\/j.kint.2017.03.026","journal-title":"Kidney Int"},{"key":"4869_CR60","doi-asserted-by":"publisher","first-page":"112","DOI":"10.2215\/CJN.00910306","volume":"2","author":"VE Torres","year":"2007","unstructured":"Torres VE, King BF, Chapman AB, Brummer ME, Bae KT, Glockner JF, Arya K, Risk D, Felmlee JP, Grantham JJ, Guay-Woodford LM, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP (2007) Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2:112\u2013120. https:\/\/doi.org\/10.2215\/CJN.00910306","journal-title":"Clin J Am Soc Nephrol"},{"key":"4869_CR61","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1681\/ASN.2018121227","volume":"30","author":"SS Hayek","year":"2019","unstructured":"Hayek SS, Landsittel DP, Wei C, Zeier M, Yu ASL, Torres VE, Roth S, Pao CS, Reiser J (2019) Soluble urokinase plasminogen activator receptor and decline in kidney function in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 30:1305\u20131313. https:\/\/doi.org\/10.1681\/ASN.2018121227","journal-title":"J Am Soc Nephrol"},{"key":"4869_CR62","doi-asserted-by":"publisher","first-page":"6927456","DOI":"10.1155\/2019\/6927456","volume":"2019","author":"T Shuai","year":"2019","unstructured":"Shuai T, Yan P, Xiong H, Huang Q, Zhu L, Yang K, Liu J (2019) Association between soluble urokinase-type plasminogen activator receptor levels and chronic kidney disease: a systematic review and meta-analysis. Biomed Res Int 2019:6927456. https:\/\/doi.org\/10.1155\/2019\/6927456","journal-title":"Biomed Res Int"},{"key":"4869_CR63","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1053\/j.ajkd.2010.06.023","volume":"56","author":"E Meijer","year":"2010","unstructured":"Meijer E, Boertien WE, Nauta FL, Bakker SJL, Van Oeveren W, Rook M, Van Der Jagt EJ, Van Goor H, Peters DJM, Navis G, De Jong PE, Gansevoort RT (2010) Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Am J Kidney Dis 56:883\u2013895. https:\/\/doi.org\/10.1053\/j.ajkd.2010.06.023","journal-title":"Am J Kidney Dis"},{"key":"4869_CR64","doi-asserted-by":"publisher","first-page":"e53016","DOI":"10.1371\/journal.pone.0053016","volume":"8","author":"AD Kistler","year":"2013","unstructured":"Kistler AD, Serra AL, Siwy J, Poster D, Krauer F, Torres VE, Mrug M, Grantham JJ, Bae KT, Bost JE, Mullen W, W\u00fcthrich RP, Mischak H, Chapman AB (2013) Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS One 8:e53016. https:\/\/doi.org\/10.1371\/journal.pone.0053016","journal-title":"PLoS One"},{"key":"4869_CR65","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/ki.2010.175","volume":"78","author":"J Zhou","year":"2010","unstructured":"Zhou J, Ouyang X, Cui X, Schoeb TR, Smythies LE, Johnson MR, Guay-Woodford LM, Chapman AB, Mrug M (2010) Renal CD14 expression correlates with the progression of cystic kidney disease. Kidney Int 78:550\u2013560. https:\/\/doi.org\/10.1038\/ki.2010.175","journal-title":"Kidney Int"},{"key":"4869_CR66","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1681\/ASN.2018060590","volume":"29","author":"FT Chebib","year":"2018","unstructured":"Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE (2018) A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol 29:2458\u20132470. https:\/\/doi.org\/10.1681\/ASN.2018060590","journal-title":"J Am Soc Nephrol"},{"key":"4869_CR67","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, Bae KT, Chapman AB, Grantham JJ, Mrug M, Hogan MC, El-Zoghby ZM, Harris PC, Erickson BJ, King BF, Torres VE (2015) Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 26:160\u2013172. https:\/\/doi.org\/10.1681\/ASN.2013101138","journal-title":"J Am Soc Nephrol"},{"key":"4869_CR68","unstructured":"Imaging classification of ADPKD: a simple model for selecting patients for clinical trials. https:\/\/www.mayo.edu\/research\/documents\/pkd-center-adpkd-classification\/doc-20094754"},{"key":"4869_CR69","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12882-017-0804-2","volume":"19","author":"P McEwan","year":"2018","unstructured":"McEwan P, Bennett Wilton H, Ong ACM, \u00d8rskov B, Sandford R, Scolari F, Cabrera MCV, Walz G, O\u2019Reilly K, Robinson P (2018) A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model. BMC Nephrol 19:37. https:\/\/doi.org\/10.1186\/s12882-017-0804-2","journal-title":"BMC Nephrol"},{"key":"4869_CR70","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.ekir.2019.05.015","volume":"4","author":"S De Rechter","year":"2019","unstructured":"De Rechter S, Bockenhauer D, Guay-Woodford LM, Liu I, Mallett AJ, Soliman NA, Sylvestre LC, Schaefer F, Liebau MC, Mekahli D, Adamczyk P, Akinci N, Alpay H, Ardelean C, Ayasreh N, Aydin Z, Bael A, Baudouin V, Bayrakci US, Bensman A, Bialkevich H, Biebuyck A, Boyer O, Bjanid O, Bry\u0142ka A, \u00c7al\u0131\u015fkan S, Cambier A, Camelio A, Carbone V, Charbit M, Chiodini B, Chirita A, \u00c7i\u00e7ek N, Cerkauskiene R, Collard L, Concei\u00e7ao M, Constantinescu I, Couderc A, Crapella B, Cvetkovic M, Dima B, Diomeda F, Docx M, Dolan N, Dossier C, Drozdz D, Drube J, Dunand O, Dusan P, Eid LA, Emma F, Espino Hernandez M, Fila M, Furlano M, Gafencu M, Ghuysen MS, Giani M, Giordano M, Girisgen I, Godefroid N, Godron-Dubrasquet A, Gojkovic I, Gonzalez E, G\u00f6k\u00e7e I, Groothoff JW, Guarino S, Guffens A, Hansen P, Harambat J, Haumann S, He G, Heidet L, Helmy R, Hemery F, Hooman N, llanas B, Jankauskiene A, Janssens P, Karamaria S, Kazyra I, Koenig J, Krid S, Krug P, Kwon V, La Manna A, Leroy V, Litwin M, Lombet J, Longo G, Lungu AC, Mallawaarachchi A, Marin A, Marzuillo P, Massella L, Mastrangelo A, McCarthy H, Miklaszewska M, Moczulska A, Montini G, Morawiec-Knysak A, Morin D, Murer L, Negru I, Nobili F, Obrycki L, Otoukesh H, \u00d6zcan S, Pape L, Papizh S, Parvex P, Pawlak-Bratkowska M, Prikhodina L, Prytula A, Quinlan C, Raes A, Ranchin B, Ranguelov N, Repeckiene R, Ronit C, Salomon R, Santagelo R, Sayg\u0131l\u0131 SK, Schaefer S, Schreuder M, Schurmans T, Seeman T, Segers N, Sinha M, Snauwaert E, Spasojevic B, Stabouli S, Stoica C, Stroescu R, Szczepanik E, Szczepa\u0144ska M, Taranta-Janusz K, Teixeira A, Thumfart J, Tkaczyk M, Torra R, Torres D, Tram N, Utsch B, Vande Walle J, Vieux R, Vitkevic R, Wilhelm-Bals A, W\u00fchl E, Yildirim ZY, Y\u00fcksel S, Zachwieja K (2019) ADPedKD: a global online platform on the management of children with ADPKD. Kidney Int Rep 4:1271\u20131284. https:\/\/doi.org\/10.1016\/j.ekir.2019.05.015","journal-title":"Kidney Int Rep"},{"key":"4869_CR71","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2215\/CJN.00080605","volume":"1","author":"KT Bae","year":"2006","unstructured":"Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, Baumgarten DA, King BF, Wetzel LH, Kenney PJ, Brummer ME, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP (2006) Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 1:64\u201369. https:\/\/doi.org\/10.2215\/CJN.00080605","journal-title":"Clin J Am Soc Nephrol"},{"key":"4869_CR72","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/hep.1840110619","volume":"11","author":"PA Gabow","year":"1990","unstructured":"Gabow PA, Johnson AM, Kaehny WD, Manco-Johnson ML, Duley IT, Everson GT (1990) Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease. Hepatology 11:1033\u20131037. https:\/\/doi.org\/10.1002\/hep.1840110619","journal-title":"Hepatology"},{"key":"4869_CR73","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/ndt\/gfw008","volume":"31","author":"FT Chebib","year":"2016","unstructured":"Chebib FT, Jung Y, Heyer CM, Irazabal MV, Hogan MC, Harris PC, Torres VE, El-Zoghby ZM (2016) Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 31:952\u2013960. https:\/\/doi.org\/10.1093\/ndt\/gfw008","journal-title":"Nephrol Dial Transplant"},{"key":"4869_CR74","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1681\/ASN.2005060645","volume":"17","author":"T Yamaguchi","year":"2006","unstructured":"Yamaguchi T, Hempson SJ, Reif GA, Hedge A-M, Wallace DP (2006) Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol 17:178\u2013187. https:\/\/doi.org\/10.1681\/ASN.2005060645","journal-title":"J Am Soc Nephrol"},{"key":"4869_CR75","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ndt\/gfv456","volume":"31","author":"RT Gansevoort","year":"2016","unstructured":"Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, Devuyst O, Drechsler C, Eckardt KU, Emma F, Knebelmann B, Le Meur Y, Massy ZA, Ong ACM, Ortiz A, Schaefer F, Torra R, Vanholder R, Wi\u0119cek A, Zoccali C, Van Biesen W (2016) Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant 31:337\u2013348. https:\/\/doi.org\/10.1093\/ndt\/gfv456","journal-title":"Nephrol Dial Transplant"},{"key":"4869_CR76","doi-asserted-by":"publisher","unstructured":"Raina R, Chakraborty R, DeCoy ME, Kline T (2020) Autosomal-dominant polycystic kidney disease: tolvaptan use in adolescents and young adults with rapid progression. Pediatr Res. https:\/\/doi.org\/10.1038\/s41390-020-0942-2","DOI":"10.1038\/s41390-020-0942-2"},{"key":"4869_CR77","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00431-019-03384-x","volume":"178","author":"F Schaefer","year":"2019","unstructured":"Schaefer F, Mekahli D, Emma F, Gilbert RD, Bockenhauer D, Cadnapaphornchai MA, Shi L, Dandurand A, Sikes K, Shoaf SE (2019) Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial. Eur J Pediatr 178:1013\u20131021. https:\/\/doi.org\/10.1007\/s00431-019-03384-x","journal-title":"Eur J Pediatr"},{"key":"4869_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0209186","volume":"14","author":"PS Sagar","year":"2019","unstructured":"Sagar PS, Zhang J, Luciuk M, Mannix C, Wong ATY, Rangan GK (2019) Increased water intake reduces long-term renal and cardiovascular disease progression in experimental polycystic kidney disease. PLoS One 14:1\u201318. https:\/\/doi.org\/10.1371\/journal.pone.0209186","journal-title":"PLoS One"},{"key":"4869_CR79","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/ndt\/gfu093","volume":"29","author":"E Higashihara","year":"2014","unstructured":"Higashihara E, Nutahara K, Tanbo M, Hara H, Miyazaki I, Kobayashi K, Nitatori T (2014) Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Nephrol Dial Transplant 29:1710\u20131719. https:\/\/doi.org\/10.1093\/ndt\/gfu093","journal-title":"Nephrol Dial Transplant"},{"key":"4869_CR80","doi-asserted-by":"publisher","first-page":"e022859","DOI":"10.1136\/bmjopen-2018-022859","volume":"8","author":"R El-Damanawi","year":"2018","unstructured":"El-Damanawi R, Lee M, Harris T, Mader LB, Bond S, Pavey H, Sandford RN, Wilkinson IB, Burrows A, Woznowski P, Ben-Shlomo Y, Karet Frankl FE, Hiemstra TF (2018) Randomised controlled trial of high versus ad libitum water intake in patients with autosomal dominant polycystic kidney disease: rationale and design of the DRINK feasibility trial. BMJ Open 8:e022859. https:\/\/doi.org\/10.1136\/bmjopen-2018-022859","journal-title":"BMJ Open"},{"key":"4869_CR81","doi-asserted-by":"publisher","first-page":"e018794","DOI":"10.1136\/bmjopen-2017-018794","volume":"8","author":"ATY Wong","year":"2018","unstructured":"Wong ATY, Mannix C, Grantham JJ, Allman-Farinelli M, Badve SV, Boudville N, Byth K, Chan J, Coulshed S, Edwards ME, Erickson BJ, Fernando M, Foster S, Haloob I, Harris DCH, Hawley CM, Hill J, Howard K, Howell M, Jiang SH, Johnson DW, Kline TL, Kumar K, Lee VW, Lonergan M, Mai J, McCloud P, Peduto A, Rangan A, Roger SD, Sud K, Torres V, Vliayuri E, Rangan GK (2018) Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). BMJ Open 8:e018794. https:\/\/doi.org\/10.1136\/bmjopen-2017-018794","journal-title":"BMJ Open"},{"key":"4869_CR82","doi-asserted-by":"publisher","first-page":"e032620","DOI":"10.1136\/bmjopen-2019-032620","volume":"10","author":"J Griffiths","year":"2020","unstructured":"Griffiths J, Mills MT, Ong ACM (2020) Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis. BMJ Open 10:e032620. https:\/\/doi.org\/10.1136\/bmjopen-2019-032620","journal-title":"BMJ Open"},{"key":"4869_CR83","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000341263","volume":"36","author":"I Helal","year":"2012","unstructured":"Helal I, Reed B, Schrier RW (2012) Emergent early markers of renal progression in autosomal-dominant polycystic kidney disease patients: implications for prevention and treatment. Am J Nephrol 36:162\u2013167. https:\/\/doi.org\/10.1159\/000341263","journal-title":"Am J Nephrol"},{"key":"4869_CR84","doi-asserted-by":"publisher","first-page":"F854","DOI":"10.1152\/ajprenal.00059.2007","volume":"293","author":"I Zafar","year":"2007","unstructured":"Zafar I, Tao Y, Falk S, McFann K, Schrier RW, Edelstein CL (2007) Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Ren Physiol 293:F854\u2013F859. https:\/\/doi.org\/10.1152\/ajprenal.00059.2007","journal-title":"Am J Physiol Ren Physiol"},{"key":"4869_CR85","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/MJT.0b013e31819cdc86","volume":"17","author":"C Palaniswamy","year":"2010","unstructured":"Palaniswamy C, Selvaraj DR, Selvaraj T, Sukhija R (2010) Mechanisms underlying pleiotropic effects of statins. Am J Ther 17:75\u201378","journal-title":"Am J Ther"},{"key":"4869_CR86","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3389\/fped.2017.00053","volume":"5","author":"MA Cadnapaphornchai","year":"2017","unstructured":"Cadnapaphornchai MA (2017) Clinical trials in pediatric autosomal dominant polycystic kidney disease. Front Pediatr 5:53. https:\/\/doi.org\/10.3389\/fped.2017.00053","journal-title":"Front Pediatr"},{"key":"4869_CR87","first-page":"2019-vol5","volume":"36","author":"S Celentano","year":"2019","unstructured":"Celentano S, Capolongo G, Pollastro RM (2019) Bardoxolone: a new potential therapeutic agent in the treatment of autosomal dominant polycystic kidney disease? G Ital Nefrol 36:2019-vol5","journal-title":"G Ital Nefrol"},{"key":"4869_CR88","doi-asserted-by":"publisher","first-page":"9245","DOI":"10.1038\/s41598-019-45539-8","volume":"9","author":"T Fujiki","year":"2019","unstructured":"Fujiki T, Ando F, Murakami K, Isobe K, Mori T, Susa K, Nomura N, Sohara E, Rai T, Uchida S (2019) Tolvaptan activates the Nrf2\/HO-1 antioxidant pathway through PERK phosphorylation. Sci Rep 9:9245. https:\/\/doi.org\/10.1038\/s41598-019-45539-8","journal-title":"Sci Rep"},{"key":"4869_CR89","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000488807","volume":"47","author":"SL Seliger","year":"2018","unstructured":"Seliger SL, Abebe KZ, Hallows KR, Miskulin DC, Perrone RD, Watnick T, Bae KT (2018) A randomized clinical trial of metformin to treat autosomal dominant polycystic kidney disease. Am J Nephrol 47:352\u2013360. https:\/\/doi.org\/10.1159\/000488807","journal-title":"Am J Nephrol"},{"key":"4869_CR90","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2215\/CJN.08350813","volume":"9","author":"MA Cadnapaphornchai","year":"2014","unstructured":"Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD, Schrier RW (2014) Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 9:889\u2013896. https:\/\/doi.org\/10.2215\/CJN.08350813","journal-title":"Clin J Am Soc Nephrol"},{"key":"4869_CR91","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2174\/1573402113666170427142815","volume":"13","author":"GM Brosnahan","year":"2017","unstructured":"Brosnahan GM, Abebe KZ, Rahbari-Oskoui FF, Patterson CG, Bae KT, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Perrone RD, Steinman TI, Torres VE (2017) Effect of Statin therapy on the progression of autosomal dominant polycystic kidney disease. a secondary analysis of the HALT PKD trials. Curr Hypertens Rev 13:109\u2013120. https:\/\/doi.org\/10.2174\/1573402113666170427142815","journal-title":"Curr Hypertens Rev"},{"key":"4869_CR92","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.1073\/pnas.0509694103","volume":"103","author":"JM Shillingford","year":"2006","unstructured":"Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T (2006) The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 103:5466\u20135471. https:\/\/doi.org\/10.1073\/pnas.0509694103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4869_CR93","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1681\/ASN.2009040421","volume":"21","author":"JM Shillingford","year":"2010","unstructured":"Shillingford JM, Piontek KB, Germino GG, Weimbs T (2010) Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol 21:489\u2013497. https:\/\/doi.org\/10.1681\/ASN.2009040421","journal-title":"J Am Soc Nephrol"},{"key":"4869_CR94","doi-asserted-by":"publisher","first-page":"785","DOI":"10.2215\/CJN.09900915","volume":"11","author":"P Ruggenenti","year":"2016","unstructured":"Ruggenenti P, Gentile G, Perico N, Perna A, Barcella L, Trillini M, Cortinovis M, Ferrer Siles CP, Reyes Loaeza JA, Aparicio MC, Fasolini G, Gaspari F, Martinetti D, Carrara F, Rubis N, Prandini S, Caroli A, Sharma K, Antiga L, Remuzzi A, Remuzzi G (2016) Effect of sirolimus on disease progression in patients with autosomal dominant polycystic kidney disease and CKD stages 3b-4. Clin J Am Soc Nephrol 11:785\u2013794. https:\/\/doi.org\/10.2215\/CJN.09900915","journal-title":"Clin J Am Soc Nephrol"},{"key":"4869_CR95","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/NEJMoa0907419","volume":"363","author":"AL Serra","year":"2010","unstructured":"Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, W\u00fcthrich RP (2010) Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363:820\u2013829. https:\/\/doi.org\/10.1056\/NEJMoa0907419","journal-title":"N Engl J Med"},{"key":"4869_CR96","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41581-018-0051-1","volume":"14","author":"V Padovano","year":"2018","unstructured":"Padovano V, Podrini C, Boletta A, Caplan MJ (2018) Metabolism and mitochondria in polycystic kidney disease research and therapy. Nat Rev Nephrol 14:678\u2013687","journal-title":"Nat Rev Nephrol"},{"key":"4869_CR97","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nm.3092","volume":"19","author":"I Rowe","year":"2013","unstructured":"Rowe I, Chiaravalli M, Mannella V, Ulisse V, Quilici G, Pema M, Song XW, Xu H, Mari S, Qian F, Pei Y, Musco G, Boletta A (2013) Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med 19:488\u2013493. https:\/\/doi.org\/10.1038\/nm.3092","journal-title":"Nat Med"},{"key":"4869_CR98","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2215\/CJN.13291019","volume":"15","author":"KL Nowak","year":"2020","unstructured":"Nowak KL, Hopp K (2020) Metabolic reprogramming in autosomal dominant polycystic kidney disease: evidence and therapeutic potential. Clin J Am Soc Nephrol 15:577\u2013584. https:\/\/doi.org\/10.2215\/CJN.13291019","journal-title":"Clin J Am Soc Nephrol"},{"key":"4869_CR99","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fped.2017.00080","volume":"5","author":"B Alzarka","year":"2017","unstructured":"Alzarka B, Morizono H, Bollman JW, Kim D, Guay-Woodford LM (2017) Design and implementation of the hepatorenal fibrocystic disease core center clinical database: a centralized resource for characterizing autosomal recessive polycystic kidney disease and other hepatorenal fibrocystic diseases. Front Pediatr 5:80. https:\/\/doi.org\/10.3389\/fped.2017.00080","journal-title":"Front Pediatr"},{"key":"4869_CR100","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ng.3871","volume":"49","author":"H Lu","year":"2017","unstructured":"Lu H, Galeano MCR, Ott E, Kaeslin G, Kausalya PJ, Kramer C, Ortiz-Br\u00fcchle N, Hilger N, Metzis V, Hiersche M, Tay SY, Tunningley R, Vij S, Courtney AD, Whittle B, W\u00fchl E, Vester U, Hartleben B, Neuber S, Frank V, Little MH, Epting D, Papathanasiou P, Perkins AC, Wright GD, Hunziker W, Gee HY, Otto EA, Zerres K, Hildebrandt F, Roy S, Wicking C, Bergmann C (2017) Mutations in DZIP1L, which encodes a ciliary-transition-zone protein, cause autosomal recessive polycystic kidney disease. Nat Genet 49:1025\u20131034. https:\/\/doi.org\/10.1038\/ng.3871","journal-title":"Nat Genet"},{"key":"4869_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.md.0000200165.90373.9a","volume":"85","author":"M Adeva","year":"2006","unstructured":"Adeva M, El-Youssef M, Rossetti S, Kamath PS, Kubly V, Consugar MB, Milliner DM, King BF, Torres VE, Harris PC (2006) Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore) 85:1\u201321. https:\/\/doi.org\/10.1097\/01.md.0000200165.90373.9a","journal-title":"Medicine (Baltimore)"},{"key":"4869_CR102","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fped.2017.00124","volume":"5","author":"A Wehrman","year":"2017","unstructured":"Wehrman A, Kriegermeier A, Wen J (2017) Diagnosis and management of hepatobiliary complications in autosomal recessive polycystic kidney disease. Front Pediatr 5:124. https:\/\/doi.org\/10.3389\/fped.2017.00124","journal-title":"Front Pediatr"},{"key":"4869_CR103","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/ng833","volume":"30","author":"CJ Ward","year":"2002","unstructured":"Ward CJ, Hogan MC, Rossetti S, Walker D, Sneddon T, Wang X, Kubly V, Cunningham JM, Bacallao R, Ishibashi M, Milliner DS, Torres VE, Harris PC (2002) The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet 30:259\u2013269. https:\/\/doi.org\/10.1038\/ng833","journal-title":"Nat Genet"},{"key":"4869_CR104","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1136\/jmg.2005.032318","volume":"14","author":"C Bergmann","year":"2003","unstructured":"Bergmann C, Senderek J, Sedlacek B, Pegiazoglou I, Puglia P, Eggermann T, Rudnik-Sch\u00f6neborn S, Furu L, Onuchic LF, De Baca M, Germino GG, Guay-Woodford L, Somlo S, Moser M, B\u00fcttner R, Zerres K (2003) Spectrum of mutations in the gene for autosomal recessive polycystic kidney disease (ARPKD\/PKHD1). J Am Soc Nephrol 14:76\u201389. https:\/\/doi.org\/10.1136\/jmg.2005.032318","journal-title":"J Am Soc Nephrol"},{"key":"4869_CR105","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1097\/01.ASN.0000078805.87038.05","volume":"14","author":"L Furu","year":"2003","unstructured":"Furu L, Onuchic LF, Gharavi A, Hou X, Esquivel EL, Nagasawa Y, Bergmann C, Senderek J, Avner E, Zerres K, Germino GG, Guay-Woodford LM, Somlo S (2003) Milder presentation of recessive polycystic kidney disease requires presence of amino acid substitution mutations. J Am Soc Nephrol 14:2004\u20132014","journal-title":"J Am Soc Nephrol"},{"key":"4869_CR106","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jpeds.2018.03.052","volume":"199","author":"K Burgmaier","year":"2018","unstructured":"Burgmaier K, Kunzmann K, Ariceta G, Bergmann C, Buescher AK, Burgmaier M, Dursun I, Duzova A, Eid L, Erger F, Feldkoetter M, Galiano M, Ge\u00dfner M, Goebel H, Gokce I, Haffner D, Hooman N, Hoppe B, Jankauskiene A, Klaus G, K\u00f6nig J, Litwin M, Massella L, Mekahli D, Melek E, Mir S, Pape L, Prikhodina L, Ranchin B, Schild R, Seeman T, Sever L, Shroff R, Soliman NA, Stabouli S, Stanczyk M, Tabel Y, Taranta-Janusz K, Testa S, Thumfart J, Topaloglu R, Weber LT, Wicher D, W\u00fchl E, Wygoda S, Yilmaz A, Zachwieja K, Zagozdzon I, Zerres K, Ranguelov N, Godefroid N, Collard L, Lombet J, Maquet J, Schalk G, Querfeld U, Beck BB, Benzing T, Buettner R, Grundmann F, Kurschat C, Benz K, Tzschoppe A, Buchholz B, Buescher R, H\u00e4ffner K, Pohl M, Gross O, Kr\u00fcgel J, Stock J, Patzer L, Oh J, Bernhardt W, Doyon A, Vinke T, Sander A, Henn M, Derichs U, Beetz R, Jeck N, Lange-Sperandio B, Ponsel S, Kusser F, Uetz B, Benz M, Schmidt S, Huppertz-Kessler C, Kranz B, Titieni A, Wurm D, Leichter HE, Bald M, Billing H, Nabhan MM, Lara LE, Papachristou F, Emma F, Cerkauskiene R, Azukaitis K, Wasilewska A, Balasz-Chmielewska I, Miklaszewska M, Tkaczyk M, Sikora P, Zaniew M, Niemirska A, Antoniewicz J, Lesiak J, Afonso AC, Teixeira A, Milosevski-Lomic G, Paripovi\u0107 D, Peco-Antic A, Papizh S, Bayazit AK, Anarat A, Soylu A, Kavukcu S, Candan C, Caliskan S, Canpolat N, Emre S, Alpay H, Akinci N, Conkar S, Poyrazoglu HM, Dusunsel R, D\u00f6tsch J, Schaefer F, Liebau MC (2018) Risk factors for early dialysis dependency in autosomal recessive polycystic kidney disease. J Pediatr 199:22\u201328.e6. https:\/\/doi.org\/10.1016\/j.jpeds.2018.03.052","journal-title":"J Pediatr"},{"key":"4869_CR107","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00467-017-3648-x","volume":"32","author":"K Ebner","year":"2017","unstructured":"Ebner K, Dafinger C, Ortiz-Bruechle N, Koerber F, Schermer B, Benzing T, D\u00f6tsch J, Zerres K, Weber LT, Beck BB, Liebau MC (2017) Challenges in establishing genotype\u2013phenotype correlations in ARPKD: case report on a toddler with two severe PKHD1 mutations. Pediatr Nephrol 32:1269\u20131273. https:\/\/doi.org\/10.1007\/s00467-017-3648-x","journal-title":"Pediatr Nephrol"},{"key":"4869_CR108","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1399-0004.1995.tb04305.x","volume":"47","author":"F Deget","year":"1995","unstructured":"Deget F, Rudnik-Schaneborn S, Zerres K (1995) Course of autosomal recessive polycystic kidney disease (ARPKD) in siblings: a clinical comparison of 20 sibships. Clin Genet 47:248\u2013253","journal-title":"Clin Genet"},{"key":"4869_CR109","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1152\/physiolgenomics.00187.2011","volume":"44","author":"CC O\u2019Meara","year":"2012","unstructured":"O\u2019Meara CC, Hoffman M, Sweeney WE Jr, Tsaih SW, Xiao B, Jacob HJ, Avner ED, Moreno C (2012) Role of genetic modifiers in an orthologous rat model of ARPKD. Physiol Genomics 44:741\u2013753. https:\/\/doi.org\/10.1152\/physiolgenomics.00187.2011","journal-title":"Physiol Genomics"},{"key":"4869_CR110","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.bbadis.2018.11.003","volume":"1865","author":"T Richards","year":"2019","unstructured":"Richards T, Modarage K, Dean C, McCarthy-Boxer A, Hilton H, Esapa C, Norman J, Wilson P, Goggolidou P (2019) Atmin modulates Pkhd1 expression and may mediate autosomal recessive polycystic kidney disease (ARPKD) through altered non-canonical Wnt\/Planar Cell Polarity (PCP) signalling. Biochim Biophys Acta Mol basis Dis 1865:378\u2013390. https:\/\/doi.org\/10.1016\/j.bbadis.2018.11.003","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"key":"4869_CR111","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1681\/ASN.2004121083","volume":"16","author":"M Mrug","year":"2005","unstructured":"Mrug M, Li R, Cui X, Schoeb TR, Churchill GA, Guay-Woodford LM (2005) Kinesin family member 12 is a candidate polycystic kidney disease modifier in the cpk mouse. J Am Soc Nephrol 16:905\u2013916. https:\/\/doi.org\/10.1681\/ASN.2004121083","journal-title":"J Am Soc Nephrol"},{"key":"4869_CR112","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1006\/geno.1999.5830","volume":"58","author":"P Upadhya","year":"1999","unstructured":"Upadhya P, Churchill G, Birkenmeier EH, Barker JE, Frankel WN (1999) Genetic modifiers of polycystic kidney disease in intersubspecific KAT2J mutants. Genomics 58:129\u2013137. https:\/\/doi.org\/10.1006\/geno.1999.5830","journal-title":"Genomics"},{"key":"4869_CR113","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1681\/ASN.2019020150","volume":"30","author":"RJ Olson","year":"2019","unstructured":"Olson RJ, Hopp K, Wells H, Smith JM, Furtado J, Constans MM, Escobar DL, Geurts AM, Torres VE, Harris PC (2019) Synergistic genetic interactions between pkhd1 and pkd1 result in an ARPKD-like phenotype in murine models. J Am Soc Nephrol 30:2113\u20132127. https:\/\/doi.org\/10.1681\/ASN.2019020150","journal-title":"J Am Soc Nephrol"},{"key":"4869_CR114","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/hmg\/ddm141","volume":"16","author":"MA Garcia-Gonzalez","year":"2007","unstructured":"Garcia-Gonzalez MA, Menezes LF, Piontek KB, Kaimori J, Huso DL, Watnick T, Onuchic LF, Guay-Woodford LM, Germino GG (2007) Genetic interaction studies link autosomal dominant and recessive polycystic kidney disease in a common pathway. Hum Mol Genet 16:1940\u20131950. https:\/\/doi.org\/10.1093\/hmg\/ddm141","journal-title":"Hum Mol Genet"},{"key":"4869_CR115","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.jpeds.2014.06.015","volume":"165","author":"LM Guay-Woodford","year":"2014","unstructured":"Guay-Woodford LM, Bissler JJ, Braun MC, Bockenhauer D, Cadnapaphornchai MA, Dell KM, Kerecuk L, Liebau MC, Alonso-Peclet MH, Shneider B, Emre S, Heller T, Kamath BM, Murray KF, Moise K, Eichenwald EE, Evans J, Keller RL, Wilkins-Haug L, Bergmann C, Gunay-Aygun M, Hooper SR, Hardy KK, Hartung EA, Streisand R, Perrone R, Moxey-Mims M (2014) Consensus expert recommendations for the diagnosis and management of autosomal recessive polycystic kidney disease: report of an international conference. J Pediatr 165:611\u2013617. https:\/\/doi.org\/10.1016\/j.jpeds.2014.06.015","journal-title":"J Pediatr"},{"key":"4869_CR116","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00467-018-3992-5","volume":"33","author":"T Szab\u00f3","year":"2018","unstructured":"Szab\u00f3 T, Orosz P, Balogh E, J\u00e1vorszky E, M\u00e1ttyus I, Bereczki C, Mar\u00f3ti Z, Kalm\u00e1r T, Szab\u00f3 AJ, Reusz G, V\u00e1rkonyi I, Mari\u00e1n E, Gombos \u00c9, Orosz O, Madar L, Balla G, Kappelmayer J, Tory K, Balogh I (2018) Comprehensive genetic testing in children with a clinical diagnosis of ARPKD identifies phenocopies. Pediatr Nephrol 33:1713\u20131721. https:\/\/doi.org\/10.1007\/s00467-018-3992-5","journal-title":"Pediatr Nephrol"},{"key":"4869_CR117","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1542\/peds.111.5.1072","volume":"111","author":"LM Guay-Woodford","year":"2003","unstructured":"Guay-Woodford LM, Desmond RA (2003) Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics 111:1072\u20131080","journal-title":"Pediatrics"},{"key":"4869_CR118","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1053\/j.ajkd.2017.12.011","volume":"71","author":"SL Furth","year":"2018","unstructured":"Furth SL, Pierce C, Hui WF, White CA, Wong CS, Schaefer F, W\u00fchl E, Abraham AG, Warady BA, Samuels J, Furth S, Atkinson M, Wilson A, Quiroga A, Massengill S, Selewski D, Ferris M, Kogon A, Kaskel F, Lande M, Schwartz G, Saland J, Norwood V, Matoo T, Hidalgo G, Srivaths P, Carlson J, Langman C, Mendley S, John E, Upadhyay K, Seo-Mayer P, Patterson L, Parekh R, Robinson L, Weinstein A, Samsonov D, Kupferman J, Misurac J, Mongia A, Kiessling S, Sanchez-Kazi C, Dart A, Fathallah S, Claes D, Mitsnefes M, Blydt-Hansen T, Warady B, Greenbaum L, Flynn J, Wong C, Salusky I, Yadin O, Dell K, Jenkins R, Pan C, Ku E, Al-Uzri A, Jenkins R, Rodig N, Wong C, Davis K, Turman M, Bartosh S, Hastings C, Nayak A, Seikaly M, Benador N, Mak R, Wood E, Jenkins R, Lerner G, Barletta GM, Anarat A, Bakkaloglu A, Ozaltin F, Peco-Antic A, Querfeld U, Gellermann J, Sallay P, Dro\u017cd\u017c D, Bonzel KE, Wingen AM, \u017burowska A, Balasz I, Trivelli A, Perfumo F, M\u00fcller-Wiefel DE, M\u00f6ller K, Offner G, Enke B, W\u00fchl E, Hadtstein C, Mehls O, Schaefer F, Emre S, Caliskan S, Mir S, Wygoda S, Hohbach-Hohenfellner K, Jeck N, Klaus G, Ardissino G, Testa S, Montini G, Charbit M, Niaudet P, Caldas-Afonso A, Fernandes-Teixeira A, Du\u0161ek J, Matteucci MC, Picca S, Mastrostefano A, Wigger M, Berg UB, Celsi G, Fischbach M, Terzic J, Fydryk J, Urasinski T, Coppo R, Peruzzi L, Arbeiter K, Jankauskien\u00e9 A, Grenda R, Litwin M, Janas R, Neuhaus TJ (2018) Estimating time to ESRD in children with CKD. Am J Kidney Dis 71:783\u2013792. https:\/\/doi.org\/10.1053\/j.ajkd.2017.12.011","journal-title":"Am J Kidney Dis"},{"key":"4869_CR119","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jpeds.2015.12.079","volume":"171","author":"KM Dell","year":"2016","unstructured":"Dell KM, Matheson M, Hartung EA, Warady BA, Furth SL (2016) Kidney disease progression in autosomal recessive polycystic kidney disease. J Pediatr 171:196\u2013201.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2015.12.079","journal-title":"J Pediatr"},{"key":"4869_CR120","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1056\/NEJMoa0902066","volume":"361","author":"E W\u00fchl","year":"2009","unstructured":"ESCAPE Trial Group, W\u00fchl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen A-M, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, M\u00f6ller K, Wigger M, Peruzzi L, Mehls O, Schaefer F (2009) Strict blood-pressure control and progression of renal failure in children. N Engl J Med 361:1639\u20131650. https:\/\/doi.org\/10.1056\/NEJMoa0902066","journal-title":"N Engl J Med"},{"key":"4869_CR121","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1651-2227.1996.tb14056.x","volume":"85","author":"K Zerres","year":"1996","unstructured":"Zerres K, Rudnik-Schoneborn S, Deget F, Holtkamp U, Brodehl J, Geisert J, Scharer K (1996) Autosomal recessive polycystic kidney disease in 115 children: clinical presentation, course and influence of gender. Arbeitsgemeinschaft fur Padiatrische, Nephrologie. Acta Paediatr 85:437\u2013445","journal-title":"Acta Paediatr"},{"key":"4869_CR122","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1007\/s00261-019-01933-4","volume":"44","author":"SD Serai","year":"2019","unstructured":"Serai SD, Otero HJ, Calle-Toro JS, Berman JI, Darge K, Hartung EA (2019) Diffusion tensor imaging of the kidney in healthy controls and in children and young adults with autosomal recessive polycystic kidney disease. Abdom Radiol 44:1867\u20131872. https:\/\/doi.org\/10.1007\/s00261-019-01933-4","journal-title":"Abdom Radiol"},{"key":"4869_CR123","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/pr.2018.24","volume":"83","author":"BO Erokwu","year":"2018","unstructured":"Erokwu BO, Anderson CE, Flask CA, Dell KM (2018) Quantitative magnetic resonance imaging assessments of autosomal recessive polycystic kidney disease progression and response to therapy in an animal model. Pediatr Res 83:1067\u20131074. https:\/\/doi.org\/10.1038\/pr.2018.24","journal-title":"Pediatr Res"},{"key":"4869_CR124","doi-asserted-by":"publisher","unstructured":"MacAskill CJ, Erokwu BO, Markley M, Parsons A, Farr S, Zhang Y, Tran U, Chen Y, Anderson CE, Serai S, Hartung EA, Wessely O, Ma D, Dell KM, Flask CA (2020) Multi-parametric MRI of kidney disease progression for autosomal recessive polycystic kidney disease: mouse model and initial patient results. Pediatr Res. https:\/\/doi.org\/10.1038\/s41390-020-0883-9","DOI":"10.1038\/s41390-020-0883-9"},{"key":"4869_CR125","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1053\/j.gastro.2012.09.056","volume":"144","author":"M Gunay-Aygun","year":"2013","unstructured":"Gunay-Aygun M, Font-Montgomery E, Lukose L, Tuchman Gerstein M, Piwnica-Worms K, Choyke P, Daryanani KT, Turkbey B, Fischer R, Bernardini I, Sincan M, Zhao X, Sandler NG, Roque A, Douek DC, Graf J, Huizing M, Bryant JC, Mohan P, Gahl WA, Heller T (2013) Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease. Gastroenterology 144:112\u2013121.e2. https:\/\/doi.org\/10.1053\/j.gastro.2012.09.056","journal-title":"Gastroenterology"},{"key":"4869_CR126","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3389\/fped.2018.00422","volume":"6","author":"D Wicher","year":"2019","unstructured":"Wicher D, Jankowska I, Lipi\u0144ski P, Szyma\u0144ska-Ro\u017cek P, Kmiotek J, Ja\u0144czyk W, Rubik J, Chrzanowska K, Socha P (2019) Transient elastography for detection of liver fibrosis in children with autosomal recessive polycystic kidney disease. Front Pediatr 6:422. https:\/\/doi.org\/10.3389\/fped.2018.00422","journal-title":"Front Pediatr"},{"key":"4869_CR127","doi-asserted-by":"publisher","unstructured":"Hartung EA, Wen J, Poznick L, Furth SL, Darge K (2019) Ultrasound elastography to quantify liver disease severity in autosomal recessive polycystic kidney disease. J Pediatr. https:\/\/doi.org\/10.1016\/j.jpeds.2019.01.055","DOI":"10.1016\/j.jpeds.2019.01.055"},{"key":"4869_CR128","doi-asserted-by":"publisher","unstructured":"Hartung EA, Calle-Toro JS, Lopera CM, Wen J, Carson RH, Dutt M, Howarth K, Furth SL, Darge K, Serai SD (2020) Magnetic resonance elastography to quantify liver disease severity in autosomal recessive polycystic kidney disease. Abdom Radiol. https:\/\/doi.org\/10.1007\/s00261-020-02694-1","DOI":"10.1007\/s00261-020-02694-1"},{"key":"4869_CR129","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1007\/s00467-010-1621-z","volume":"25","author":"M Goto","year":"2010","unstructured":"Goto M, Hoxha N, Osman R, Dell KM (2010) The renin-angiotensin system and hypertension in autosomal recessive polycystic kidney disease. Pediatr Nephrol 25:2449\u20132457. https:\/\/doi.org\/10.1007\/s00467-010-1621-z","journal-title":"Pediatr Nephrol"},{"key":"4869_CR130","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/MPG.0b013e3181cc80e4","volume":"50","author":"M Goto","year":"2010","unstructured":"Goto M, Hoxha N, Osman R, Wen J, Wells RG, Dell KM (2010) Renin-angiotensin system activation in congenital hepatic fibrosis in the PCK rat model of autosomal recessive polycystic kidney disease. J Pediatr Gastroenterol Nutr 50:639\u2013644. https:\/\/doi.org\/10.1097\/MPG.0b013e3181cc80e4","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"4869_CR131","doi-asserted-by":"publisher","first-page":"e81480","DOI":"10.1371\/journal.pone.0081480","volume":"8","author":"D Yoshihara","year":"2013","unstructured":"Yoshihara D, Kugita M, Sasaki M, Horie S, Nakanishi K, Abe T, Aukema HM, Yamaguchi T, Nagao S (2013) Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. PLoS One 8:e81480. https:\/\/doi.org\/10.1371\/journal.pone.0081480","journal-title":"PLoS One"},{"key":"4869_CR132","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1681\/ASN.2006030251","volume":"17","author":"S Nagao","year":"2006","unstructured":"Nagao S, Nishii K, Katsuyama M, Kurahashi H, Marunouchi T, Takahashi H, Wallace DP (2006) Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 17:2220\u20132227. https:\/\/doi.org\/10.1681\/ASN.2006030251","journal-title":"J Am Soc Nephrol"},{"key":"4869_CR133","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1681\/ASN.2007060688","volume":"19","author":"X Wang","year":"2008","unstructured":"Wang X, Wu Y, Ward CJ, Harris PC, Torres VE (2008) Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 19:102\u2013108. https:\/\/doi.org\/10.1681\/ASN.2007060688","journal-title":"J Am Soc Nephrol"},{"key":"4869_CR134","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH Gattone","year":"2003","unstructured":"Gattone VH, Wang X, Harris PC, Torres VE (2003) Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9:1323\u20131326. https:\/\/doi.org\/10.1038\/nm935","journal-title":"Nat Med"},{"key":"4869_CR135","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1681\/ASN.2004121090","volume":"16","author":"X Wang","year":"2005","unstructured":"Wang X, Gattone V, Harris PC, Torres VE (2005) Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 16:846\u2013851. https:\/\/doi.org\/10.1681\/ASN.2004121090","journal-title":"J Am Soc Nephrol"},{"key":"4869_CR136","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1159\/000500667","volume":"49","author":"X Wang","year":"2019","unstructured":"Wang X, Constans MM, Chebib FT, Torres VE, Pellegrini L (2019) Effect of a Vasopressin V2 receptor antagonist on polycystic kidney disease development in a rat model. Am J Nephrol 49:487\u2013493. https:\/\/doi.org\/10.1159\/000500667","journal-title":"Am J Nephrol"},{"key":"4869_CR137","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/labinvest.2016.93","volume":"96","author":"R Mancinelli","year":"2016","unstructured":"Mancinelli R, Franchitto A, Glaser S, Vetuschi A, Venter J, Sferra R, Pannarale L, Olivero F, Carpino G, Alpini G, Onori P, Gaudio E (2016) Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease. Lab Investig 96:1147\u20131155. https:\/\/doi.org\/10.1038\/labinvest.2016.93","journal-title":"Lab Investig"},{"key":"4869_CR138","doi-asserted-by":"publisher","first-page":"7733","DOI":"10.1038\/s41598-017-08284-4","volume":"7","author":"J y Kaimori","year":"2017","unstructured":"Kaimori J y, Lin CC, Outeda P, Garcia-Gonzalez MA, Menezes LF, Hartung EA, Li A, Wu G, Fujita H, Sato Y, Nakanuma Y, Yamamoto S, Ichimaru N, Takahara S, Isaka Y, Watnick T, Onuchic LF, Guay-Woodford LM, Germino GG (2017) NEDD4-family E3 ligase dysfunction due to PKHD1\/Pkhd1 defects suggests a mechanistic model for ARPKD pathobiology. Sci Rep 7:7733. https:\/\/doi.org\/10.1038\/s41598-017-08284-4","journal-title":"Sci Rep"},{"key":"4869_CR139","doi-asserted-by":"publisher","first-page":"C952","DOI":"10.1152\/ajpcell.00339.2005","volume":"290","author":"D Olteanu","year":"2006","unstructured":"Olteanu D, Yoder BK, Liu W, Croyle MJ, Welty EA, Rosborough K, Wyss JM, Bell PD, Guay-Woodford LM, Bevensee MO, Satlin LM, Schwiebert EM (2006) Heightened epithelial Na+ channel-mediated Na+ absorption in a murine polycystic kidney disease model epithelium lacking apical monocilia. Am J Physiol Physiol 290:C952\u2013C963. https:\/\/doi.org\/10.1152\/ajpcell.00339.2005","journal-title":"Am J Physiol Physiol"},{"key":"4869_CR140","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/pr.2014.145","volume":"77","author":"TS Pavlov","year":"2015","unstructured":"Pavlov TS, Levchenko V, Ilatovskaya DV, Palygin O, Staruschenko A (2015) Impaired epithelial Na + channel activity contributes to cystogenesis and development of autosomal recessive polycystic kidney disease in PCK rats. Pediatr Res 77:64\u201369. https:\/\/doi.org\/10.1038\/pr.2014.145","journal-title":"Pediatr Res"},{"key":"4869_CR141","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ebiom.2019.01.006","volume":"40","author":"DV Ilatovskaya","year":"2019","unstructured":"Ilatovskaya DV, Levchenko V, Pavlov TS, Isaeva E, Klemens CA, Johnson J, Liu P, Kriegel AJ, Staruschenko A (2019) Salt-deficient diet exacerbates cystogenesis in ARPKD via epithelial sodium channel (ENaC). EBioMedicine 40:663\u2013674. https:\/\/doi.org\/10.1016\/j.ebiom.2019.01.006","journal-title":"EBioMedicine"},{"key":"4869_CR142","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/hep.26140","volume":"58","author":"TV Masyuk","year":"2013","unstructured":"Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Gradilone SA, Huang B, Masyuk AI, Hogan MC, Torres VE, Larusso NF (2013) Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology 58:409\u2013421. https:\/\/doi.org\/10.1002\/hep.26140","journal-title":"Hepatology"},{"key":"4869_CR143","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/pr.2013.191","volume":"75","author":"WE Sweeney","year":"2014","unstructured":"Sweeney WE, Avner ED (2014) Pathophysiology of childhood polycystic kidney diseases: new insights into disease-specific therapy. Pediatr Res 75:148\u2013157. https:\/\/doi.org\/10.1038\/pr.2013.191","journal-title":"Pediatr Res"},{"key":"4869_CR144","doi-asserted-by":"publisher","first-page":"188","DOI":"10.5527\/wjn.v6.i4.188","volume":"6","author":"WE Sweeney","year":"2017","unstructured":"Sweeney WE, Frost P, Avner ED (2017) Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease. World J Nephrol 6:188. https:\/\/doi.org\/10.5527\/wjn.v6.i4.188","journal-title":"World J Nephrol"},{"key":"4869_CR145","unstructured":"A safety, pharmacokinetic, single ascending dose study of tesevatinib in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD). In: ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03096080"},{"key":"4869_CR146","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12882-015-0002-z","volume":"16","author":"K Ebner","year":"2015","unstructured":"Ebner K, Feldkoetter M, Ariceta G, Bergmann C, Buettner R, Doyon A, Duzova A, Goebel H, Haffner D, Hero B, Hoppe B, Illig T, Jankauskiene A, Klopp N, K\u00f6nig J, Litwin M, Mekahli D, Ranchin B, Sander A, Testa S, Weber LT, Wicher D, Yuzbasioglu A, Zerres K, D\u00f6tsch J, Schaefer F, Liebau MC, ESCAPE Study Group; GPN Study Group (2015) Rationale, design and objectives of ARegPKD, a European ARPKD registry study. BMC Nephrol 16:22. https:\/\/doi.org\/10.1186\/s12882-015-0002-z","journal-title":"BMC Nephrol"},{"key":"4869_CR147","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1136\/amiajnl-2014-002743","volume":"21","author":"CB Forrest","year":"2014","unstructured":"Forrest CB, Margolis PA, Bailey LC, Marsolo K, Del Beccaro MA, Finkelstein JA, Milov DE, Vieland VJ, Wolf BA, Yu FB, Kahn MG (2014) PEDSnet: a national pediatric learning health system. J Am Med Inform Assoc 21:602\u2013606. https:\/\/doi.org\/10.1136\/amiajnl-2014-002743","journal-title":"J Am Med Inform Assoc"},{"key":"4869_CR148","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1053\/j.ajkd.2018.11.001","volume":"73","author":"KA Smith","year":"2019","unstructured":"Smith KA, Thompson AM, Baron DA, Broadbent ST, Lundstrom GH, Perrone RD (2019) Addressing the need for clinical trial end points in autosomal dominant polycystic kidney disease: a report from the Polycystic Kidney Disease Outcomes Consortium (PKDOC). Am J Kidney Dis 73:533\u2013541. https:\/\/doi.org\/10.1053\/j.ajkd.2018.11.001","journal-title":"Am J Kidney Dis"}],"updated-by":[{"DOI":"10.1007\/s00467-021-04971-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000}}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-020-04869-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-020-04869-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-020-04869-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T10:08:29Z","timestamp":1629194909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-020-04869-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":148,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["4869"],"URL":"https:\/\/doi.org\/10.1007\/s00467-020-04869-w","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00467-021-04971-7","asserted-by":"object"}]},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]},"assertion":[{"value":"28 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00467-021-04971-7","URL":"https:\/\/doi.org\/10.1007\/s00467-021-04971-7","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}